First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Haemonetics: the story is balanced — Plasma center utilization rates and donor traffic trends - directly impacts disposables volume which represents 45-50%…
4Plasma pricing dynamics and customer inventory destocking cycles at major customers (CSL, Grifols, Takeda)
5Margin expansion trajectory driven by manufacturing efficiency and mix shift toward higher-margin hospital products
6Plasma segment (~55-60% of revenue): Automated plasma collection devices (NexSys, PCS2) and disposable collection sets sold to commercial plasma centers operated by CSL, Grifols, Takeda
7Hospital segment (~40-45% of revenue): Blood management systems including Cell Saver (autologous blood recovery), TEG (hemostasis diagnostics), and blood bank software/disposables
8Service and maintenance contracts tied to installed equipment base
value - Stock trades at 9.9x EV/EBITDA vs medtech peer average of 14-16x, offering 30-40% valuation discount despite 20%+ ROE and improving…
Rising rates create modest headwinds through two channels: (1) Higher cost of debt refinancing - company carries $375M net debt (1.34x…
Watch on earnings: US plasma center utilization rates and donor compensation trends (industry data from PPTA, Plasma Protein Therapeutics Association), Hospital surgical procedure volumes - American Hospital Association data on cardiac, orthopedic, trauma case counts, FDA 510(k) clearance pipeline for new products (VCD, next-gen TEG devices).
One Sentence Summary:
Haemonetics: the story is balanced — plasma center utilization rates and donor traffic trends - directly impacts disposables volume which represents 45-50% of total revenue.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.